PROKIDNEY CORP.
For the period ended Jun 30, 2026. Filed Aug 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 10, 2026
PROK$1.11-3.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
Condensed Consolidated Statements of Operations - Unaudited
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenue | $150 | $221 | $376 | $451 |
| Operating expenses | ||||
| Research and development | 36,095 | 25,882 | 69,937 | 53,145 |
| General and administrative | 12,428 | 14,048 | 23,745 | 28,403 |
| Total operating expenses | 48,523 | 39,930 | 93,682 | 81,548 |
| Operating loss | (48,373) | (39,709) | (93,306) | (81,097) |
| Other income (expense): | ||||
| Interest income | 1,938 | 3,593 | 4,265 | 7,620 |
| Interest expense | (1) | (1) | (16) | (1) |
| Net loss before income taxes | (46,436) | (36,117) | (89,057) | (73,478) |
| Income tax expense | — | 848 | – | 1,439 |
| Net loss before noncontrolling interest | (46,436) | (36,965) | (89,057) | (74,917) |
| Net loss attributable to noncontrolling interest | (18,014) | (20,413) | (40,598) | (41,631) |
| Net loss available to Class A common stockholders | $(28,422) | $(16,552) | $(48,459) | $(33,286) |
| Weighted average shares of Class A common stock outstanding: | ||||
| Basic and diluted | 186,560,999 | 130,730,840 | 164,366,352 | 129,858,450 |
| Net loss per share attributable to Class A common stock: | ||||
| Basic and diluted | $(0.15) | $(0.13) | $(0.29) | $(0.26) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.